Method for activation treatment of antigen-presenting cell

Abstract

Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or γδ T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or γδ T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or γδ T cells and the number of the disease antigen-specific CD8+ CTLs and the γδ T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

1 - 10 . (canceled) 
     
     
         11 . An activated antigen-presenting cell produced by a process comprising co-pulsing an antigen-presenting cell in vitro with a bisphosphonate and a disease antigen,
 wherein the activated antigen-presenting cell is selected from the group consisting of a mature dendritic cell and an immature dendritic cell.   
     
     
         12 . A medical composition for a cancer and/or an infectious disease, the medical composition comprising:
 an activated antigen-presenting cell produced by a process comprising co-pulsing an antigen-presenting cell in vitro with a bisphosphonate and a disease antigen,   wherein the activated antigen-presenting cell is selected from the group consisting of a mature dendritic cell and an immature dendritic cell.   
     
     
         13 . The medical composition according to  claim 12 , wherein the antigen-presenting cell is an autologous antigen-presenting cell or an allogeneic antigen-presenting cell that shares the same HLA. 
     
     
         14 . The medical composition according to  claim 12 , wherein the bisphosphonate is a chemical compound of formula (I), a salt thereof or a hydrate thereof, 
       
         
           
           
               
               
           
         
         wherein: 
         R is a hydrogen atom or a C1-C10 alkyl group; and 
         R 1  and R 2  are each, independently of one another, selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a thiol group, an aryl group or a substituted aryl group, an alkyl group or a substituted alkyl group, a C1-C10 alkyl amino group, an aralkyl group, a cycloalkyl group, and a heterocyclic group, or R 1  and R 2  form part of the same cyclic structure; and 
         a substituent in R 1  and R 2  are selected from the group consisting of a halogen atom, a C1-C10 alkyl group, a hydroxyl group, a thiol group, an amino group, an alkoxy group, an aryl group, an arylthio group, an aryloxy group, an alkylthio group, a cycloalkyl group, and a heterocyclic group. 
       
     
     
         15 . The medical composition according to  claim 12 , the bisphosphonate is at least one selected from the group consisting of a zoledronic acid, a pamidronic acid, an alendronic acid, a risedronic acid, an ibandronic acid, an incadronic acid, an etidronic acid, a salt thereof and a hydrate thereof. 
     
     
         16 . The medical composition according to  claim 12 , wherein a concentration of the bisphosphonate in the co-pulse is 0.001 to 20 μM. 
     
     
         17 . The medical composition according to  claim 12 , wherein the concentration of the bisphosphonate in the co-pulse is 0.001 to 5 μM. 
     
     
         18 . The medical composition according to  claim 12 , wherein the disease antigen is at least one selected from the group consisting of a cancer antigenic protein, a cancer antigenic peptide, an infectious disease antigenic protein or an infectious disease antigenic peptide, a lysed cancer cell or a lysed infectious disease cell, and an apoptotic cell and a necrotic cell of a cancer cell or an infectious disease cell, and a heat-treated product thereof. 
     
     
         19 . The medical composition according to  claim 12 , wherein a concentration of the disease antigen in the co-pulse is 0.01 to 20 μg/ml. 
     
     
         20 . The medical composition according to  claim 12 , wherein the concentration of the disease antigen in the co-pulse is 0.1 to 2 μg/ml.